Fenofibrate and losartan

Annals of the Rheumatic Diseases

Volumn 62, Issue 6, 2003, Pages 497-498

  Bardin, T ^a  

^a HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BENZBROMARONE; FENOFIBRATE; LOSARTAN; URICOSURIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; GOUT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; PRIORITY JOURNAL; SHORT SURVEY; URIC ACID URINE LEVEL;

DRUG THERAPY, COMBINATION; GOUT SUPPRESSANTS; HUMANS; HYPERTENSION; HYPERURICEMIA; LOSARTAN; PROCETOFEN;

EID: 0037809650     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.6.497     Document Type: Short Survey

References (29)

1. Takahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003;52:572.
2. Nakashima M, Uematsu T, Kosuge K, Kanamura M. Pilot study of the uricosuric effect of DuP 753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992;42:333-5.
3. Ferris TF, Gorden P. Effect of angiotensin and norepinephrine upon urate clearance in man. Am J Med 1968;44:359-65.
4. Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994;7:1035-40.
5. Burnier M, Rutschmann B, Nussberger J, Versaggi J, Shahine S, Waeber B, et al. Salt-dependent renal effects of angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47.
6. Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268-71.
7. Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Ré R. Effect of esoprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999;17:1033-9.
8. Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi C-L, Brunner H R, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001;19:1855-60.
9. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002;417:447-52.
10. Burnier M, Roch-Ramel F, Brunner HR. Renal effects of angiotensin II receptor blockade in normotensive subjects. Kidney Int 1996;49:1787-90.
11. Grossman E, Peleg E, Caroll J, Shamiss A, Rosenthal T. Hemodynamic and humoral effect of the angiotensin II receptor antagonist losartan in essential hypertension. Am J Hypertens 1994;7:1041-4.
12. Shaninfar S, Simpson RL, Carides AD, Thiyagarajan B, Nakagawa Y, Umans JG, et al. Safety of losartan in hypertensive patients with thiazide induced hyperuricemia. Kidney Int 1999;56:1879-95.
13. Softer BA, Wright JT, Pratt H, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112-17.
14. Schoenberger JA for the losartan research group. Losartan with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995;13 (suppl):S43-7.
15. Desager JP, Hullhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 1980;20:560-4.
16. Harvengt C, Heller F, Desager JP. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemia. Artery 1980;7:73-82.
17. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 2001;28:2294-7.
18. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effects ot two fibric acid derivatives (bezafibrate and fenofibrate) in a double blind, placebo-controlled trial. Metabolism 1988;37:217-20.
19. Elsaf M, Tsichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999;34:60-3.
20. Hepburn AL, Kaye SA, Feher MD. Fenofibrate: a new treatment for hyperuricemia and gout? Ann Rheum Dis 2001;60:984-6.
21. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases. J Rheumatol 2000;27:2232-6.
22. Cappuccio FP, Strazzulo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA 1993;270:354-9.
23. Tykarski A. Evaluation of renal handling of uric acid in essential hypertension: hyperuricemia related to decreased urate secretion. Nephron 1991;59:364-8.
24. Reaven GM. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997;30:928-31.
25. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk of cardiovascular disease and mortality: the Framingham heart study. Ann Intern Med 1999;131:7-13.
26. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. The NHAMES I epidemiologic follow-up study 1971-1992. JAMA 2000;283:2404-10.
27. Liang MH, Fries JF. Asymtomatic hyperuricemia: the case for conservative management. Ann Intern Med 1978;88:666-70.
28. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6.
29. Mazzali M, Kanellis J, Han L, Feng L, Chen Q, Kang DH, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-7.